Alani Nu’s spectacular exit is one indication its proposition was not easy to replicate.
After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
The approval makes chenodiol—already cleared for decades to treat radiolucent gallstones under the brand name Chenodal—the ...
The U.S. Food and Drug Administration approved Mirum Pharmaceuticals' genetic disorder drug on Friday, making it the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback